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STATEMENT OF TRANSLATIONAL RELEVANCE 
Somatic mutation status at KRAS, BRAF and NRAS affects prognosis in patients 
with advanced colorectal cancer (aCRC) and it has been presumed that different 
variants in the same gene confer similar prognostic outcomes. Here, we studied 
inter- and intra-locus variant co-occurrence and variant-specific differences in 
survival and clinicopathology by analysing 2,157 patients with aCRC. We found 
significant differences between variants in BRAF (c.1781A>G [p.D594G] versus 
c.1799T>A [p.V600E]) and NRAS (mutant codons 12 and 13 versus codon 61) both 
in terms of co-occurrence with KRAS mutations and in their influence on survival. 
These data need to be considered in patient management and personalised therapy.
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ABSTRACT 
Purpose 
Somatic mutation status at KRAS, BRAF and NRAS is associated with prognosis in 
patients with advanced colorectal cancer (aCRC); however, it remains unclear 
whether there are intra-locus, variant-specific differences in survival and other 
clinicopathological parameters. 
 
Experimental design 
We profiled 2,157 aCRCs for somatic mutations in KRAS, BRAF and NRAS and 
determined microsatellite instability status. We sought inter- and intra-locus 
correlations between mutations, and variant-specific associations with survival and 
clinicopathology. 
 
Results 
KRAS mutations were rarely found together and those in codons 12 and 13 
conferred poor prognosis (HR 1.44, 95% CI 1.28-1.61, p=6.4e-10 and HR 1.53, 95% 
CI 1.26-1.86, p=1.5e-05, respectively). For BRAF, more c.1781A>G (p.D594G) CRCs 
carried RAS mutations (14% [3/21]) compared to c.1799T>A (p.V600E) CRCs (1% 
[2/178], p=9.0e-03). c.1799T>A (p.V600E) was associated with poor prognosis (HR 
2.60, 95% CI 2.06-3.28, p=1.0e-15), whereas c.1781A>G (p.D594G) was not (HR 
1.30, 95% CI 0.73-2.31, p=0.37); this intra-locus difference was significant (p=0.04). 
More c.1799T>A (p.V600E) CRCs were found in the right colon (47% [47/100]), 
compared to c.1781A>G (p.D594G) CRCs (7% [1/15], p=3.7e-03). For NRAS, 5% 
(3/60) of codon 61 mutant CRCs had KRAS mutations compared to 44% (10/23) of 
codons 12 and 13 mutant CRCs (p=7.9e-05). Codon 61 mutations conferred poor 
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prognosis (HR 1.47, 95% CI 1.09-1.99, p=0.01), whereas codons 12 and 13 
mutations did not (HR 1.29, 95% CI 0.64-2.58, p=0.48). 
 
Conclusions 
Our data show considerable intra-locus variation in the outcomes of mutations in 
BRAF and NRAS. These data need to be considered in patient management and 
personalised cancer therapy. 
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INTRODUCTION 
The only routinely used prognostic marker for survival after diagnosis of colorectal 
cancer (CRC) is clinical stage, which combines depth of tumour invasion, nodal 
status and distant metastasis (1). In stage 4 disease, Köhne’s index based on 
performance status, white blood cell count, alkaline phosphatase levels and number 
of metastatic sites has been proposed (2). Other factors thought to influence survival 
include lifestyle (3,4), systemic inflammatory response to the tumour (5), tumour 
immunologic environment (6), and the germline (7) and somatic (8-11) molecular 
profiles. By studying patients with advanced CRC (aCRC) from the Medical 
Research Council (MRC) COIN trial, we previously showed that the somatic mutation 
status at KRAS and BRAF, and microsatellite instability (MSI), conferred poor 
prognosis irrespective of treatment: overall survival (OS, trial enrolment to death) 
KRAS mutant 14.4 months (12), BRAF mutant 8.8 months (12), MSI 9.3 months (13), 
all wild type 20.1 months (12). We also showed that neither individual somatic 
mutations, nor mutations grouped by codon or gene, affected response to cetuximab 
(13). 
 
It remains unclear whether there are intra-locus, variant-specific differences in 
survival and this has been difficult to study for the less frequently mutated loci (such 
as c.1781A>G [p.D594G] in BRAF) due to the large numbers of samples required to 
make statistically robust associations. Here, we studied the influence of individual or 
codon specific somatic mutations in KRAS, BRAF and NRAS in 2,157 patients with 
aCRC from COIN (12) and COIN-B (14). 
 
MATERIALS AND METHODS 
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Patients and samples 
We prepared tumour DNA samples from unrelated patients with aCRC from the 
MRC clinical trials COIN (NCT00182715) (12) and COIN-B (NCT00640081) (14), as 
previously described (12,13). All patients had either previous or current histologically 
confirmed primary adenocarcinomas of the colon or rectum, together with clinical or 
radiological evidence of advanced and/or metastatic disease, or had 
histologically/cytologically confirmed metastatic adenocarcinomas, together with 
clinical and/or radiological evidence of a colorectal primary tumour. COIN patients 
were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine 
chemotherapy, continuous chemotherapy plus cetuximab, or intermittent 
chemotherapy. COIN-B patients were randomised 1:1 to receive intermittent 
chemotherapy plus continuous cetuximab or intermittent chemotherapy plus 
intermittent cetuximab. All patients gave informed consent for their samples to be 
used for bowel cancer research (approved by REC [04/MRE06/60]). 
 
Somatic analyses 
We previously screened for somatic mutations in KRAS (codons 12, 13 and 61), 
BRAF (codons 594 and 600) and NRAS (codons 12, 13 and 61) using a combination 
of Pyrosequencing and Sequenom (13); for samples analysed by both technologies 
(n=1,612), genotype concordance in KRAS was 99% (8,642/8,719 calls were 
concordant). MSI status was determined using the markers BAT-25 and BAT-26 
(13). 
 
Mutation co-occurrence, survival and statistical analyses 
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We sought inter- and intra-locus correlations between somatic KRAS, BRAF and 
NRAS mutations and MSI status. Data was analysed using R (http://www.r-
project.org). Corrplot was used to create a correlation matrix plot (recode from car 
was used to recode the data into binary format) and Survfit, survdiff and coxph.test 
from the OIsurv package and ggsurv from the GGally package were used to create 
and analyse the survival curves. To avoid potential confounding affects from other 
mutant loci, KRAS mutants (versus wild type) were analysed on a BRAF and NRAS 
wild type background; BRAF mutants (versus wild type) were analysed on a KRAS 
and NRAS (RAS) wild type and MSS background; NRAS mutants (versus wild type) 
were analysed on a KRAS and BRAF wild type background; and MSI (versus MSS) 
was analysed on a RAS and BRAF wild type background. We found no evidence of 
heterogeneity in OS between patients when analysed by trial (COIN versus COIN-B, 
p=0.49), trial arm (p=0.40 Cochran’s Q Test: p=1.0 I2 Test: p=0.74), type of 
chemotherapy received (OxMdG/XELOX) (p=0.60) or cetuximab use (p=0.41), so 
combined these groups for the survival analyses. We used Chi-square Tests or 
Fisher’s Exact Test to study whether KRAS, BRAF and NRAS mutations and MSI 
status were associated with different clinicopathological findings. We corrected for 
multiple testing using Bonferroni correction (p<1.7e-03 [n=30] for survival tests, 
p<1.0e-04 [n=480] for somatic mutation cross-correlations, p<1.3e-03 [n=39] for 
clinicopathological analyses of KRAS, BRAF and NRAS and p<3.8e-03 [n=13] for 
clinicopathological analyses of MSI). 
 
RESULTS 
We screened for somatic KRAS, BRAF and NRAS mutations and for MSI status in 
aCRCs from 2,157 patients from the clinical trials COIN and COIN-B. In total, we 
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detected 14 KRAS mutations (c.34G>A [p.G12S], c.34G>C [p.G12R], c.34G>T 
[p.G12C], c.35G>A [p.G12D], c.35G>C [p.G12A], c.35G>T [p.G12V], c.37G>A 
[p.G13S], c.37G>C [p.G13R], c.37G>T [p.G13C], c.38G>A [p.G13D], c.38G>T 
[p.G13V], c.182A>G [p.Q61R], c.182A>T [p.Q61L] and c.183A>C [p.Q61H]) in 40% 
(858/2,157) aCRCs, 2 BRAF mutations (c.1781A>G [p.D594G] and c.1799T>A 
[p.V600E]) in 9% (199/2,097), 9 NRAS mutations (c.34G>T [p.G12C], c.35G>A 
[p.G12D], c.35G>T [p.G12V], c.37G>C [p.G13R], c.38G>A [p.G13D], c.181C>A 
[p.Q61K], c.182A>G [p.Q61R], c.182A>T [p.Q61L] and c.183A>C [p.Q61H]) in 4% 
(83/2,092) and MSI in 4% (66/1,567). Over 99% (2,152/2,157) of aCRCs harbouring 
KRAS, BRAF and NRAS mutations carried only a single variant allele at their 
respective loci (five CRCs carried two KRAS mutations; however, due to their rarity, 
these were likely to reflect mixed tumour populations). 
 
Inter- and intra-genic mutation correlations 
All mutations in KRAS, regardless of whether analysed individually or by codon, 
showed similar effects in terms of mutual exclusivity (Supplementary Figure). Codon 
12 (4 of 627 mutant CRCs), 13 (4 of 161) and 61 (2 of 35) mutations were rarely 
found together. 
 
Only specific mutations in BRAF (c.1799T>A [p.V600E]) and NRAS (codon 61 
mutations) shared this characteristic. Only 1% (2/178) of BRAF c.1799T>A 
(p.V600E) CRCs had RAS mutations compared to 47% (894/1908) of BRAF wild 
type CRCs (p<2.2e-16, p<1.1e-13 after correction for multiple testing). In contrast, 
more BRAF c.1781A>G (p.D594G) mutations co-occurred with RAS mutations (14% 
[3/21]) as compared to c.1799T>A (p.V600E) (p=9.0e-03); albeit less commonly than 
10 
 
found in BRAF wild-type CRCs (p=3.0e-03). We noted one case of KRAS c.37G>A 
(p.G13S) which co-occurred with BRAF c.1799T>A (p.V600E) (p=2.5e-03 as 
compared to other KRAS mutations [1/812 co-occurred]). For NRAS, only 5% (3/60) 
of codon 61 mutant CRCs had KRAS mutations compared to 43% (10/23) of codons 
12 and 13 mutant CRCs (p=7.9e-05, p=0.04 after correction); the latter being at 
similar level to that found in wild type CRCs (40% [808/2018], p=0.98). 
 
We also observed differences in the relationship between BRAF mutations and MSI 
status. BRAF c.1799T>A (p.V600E) was strongly associated with MSI (11% [20/178] 
c.1799T>A [p.V600E] CRCs had MSI compared to 2% [46/1,908] wild type CRCs, 
p=5.3e-10, p=2.5e-07 after correction), whereas BRAF c.1781A>G (p.D594G) and MSI 
did not co-occur (0/21). 
 
Survival analyses 
Five KRAS mutations (c.34G>A [p.G12S], c.35G>A [p.G12D], c.35G>C [p.G12A], 
c.35G>T [p.G12V] and c.38G>A [p.G13D]) individually showed significantly poorer 
prognosis with a median reduction in survival of 213, 111, 65, 160 and 165 days, 
respectively; four of these remained significant after correction for multiple testing 
(Table 1). When grouped by codons, both codon 12 and 13 mutations conferred poor 
prognosis (HR 1.44, 95% CI 1.28-1.61, p=6.4e-10, p=1.9e-08 after correction, and HR 
1.53, 95% CI 1.26-1.86, p=1.5e-05, p=4.5e-04 after correction, respectively), whereas 
codon 61 mutations did not (HR 1.23, 95% CI 0.84-1.81, p=0.28) (Table 1); these 
intra-locus differences were not significant. 
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c.1799T>A (p.V600E) in BRAF was strongly associated with poor prognosis (HR 
2.60, 95% CI 2.06-3.28, p=1.0e-15, p=3.0e-14 after correction, median reduction in 
survival 320 days) (Fig.1), whereas c.1781A>G (p.D594G) was not (HR 1.30, 95% 
CI 0.73-2.31, p=0.37); this intra-locus difference was significant (p=0.04) (Table 1). 
 
Although individual NRAS mutations showed no differences in survival, when 
grouped by codon, codon 61 mutations conferred poor prognosis (HR 1.47, 95% CI 
1.09-1.99, p=0.01, median reduction in survival 131 days) (Fig.1), whereas codons 
12 and 13 mutations did not (HR 1.29, 95% CI 0.64-2.58, p=0.48); however, this 
intra-locus difference was not significant (p=0.73). 
 
Patients with MSI CRCs had worse prognosis compared to those with stable 
tumours (HR 1.86, 95% CI 1.22-2.83, p=4.0e-03), in agreement with our previous 
study (13). 
 
For all analyses described herein, there were no significant differences measured 
using heterogeneity tests when the analyses were performed using date of diagnosis 
to death instead of OS (Supplementary Table S1) or when split by cetuximab use 
(Supplementary Table S2). 
 
Clinicopathological analyses 
KRAS 
More KRAS mutant CRCs were found in the right colon (58% [182/314]) and caecum 
(70% [62/88]) as compared to the left colon (38% [123/326], p=4.6e-07 and 8.4e-08, 
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respectively) and more were associated with metastases in the lung (50% [358/715]) 
as compared to liver only (37% [156/418], p=4.2e-05) (Table 2). 
 
In terms of codon specific mutations, more KRAS codon 12 and 13 mutant CRCs 
were found in the right colon (23% [173/760] versus 13% [132/1002], p=1.9e-07) and 
caecum (8% [61/760] versus 3% [26/1002], p=3.4e-07), less in the left colon (15% 
[117/760] versus 20% [203/1002], p=0.01) and sigmoid colon (5% [41/760] versus 
11% [115/1002], p=1.3e-05) and more were associated with metastases in the lung 
(45% [342/760] versus 36% [357/1002], p=8.4e-05) and less in liver only (20% 
[152/760] versus 26% [262/1002], p=3.1e-03), as compared to wild type CRCs; the 
correlations for right colon, caecum, sigmoid colon and lung remained significant 
after correction for multiple testing (Table 2). More KRAS codon 61 mutant patients 
had CRCs in the right colon (27% [9/33] versus 13% [132/1002], p=0.04) and more 
had peritoneal metastases (27% [9/33] versus 13% [133/1002], p=0.04) as 
compared to wild type patients. However, there were no significant differences in 
clinicopathology between KRAS codons 12 and 13 versus codon 61 mutant patients. 
 
BRAF 
More BRAF mutant CRCs were found in the right colon (38% [48/128]) as compared 
to the left colon (12% [18/146], p=2.4e-05), and more were associated with 
metastases in the peritoneum (23% [25/107]) as compared to liver only (10% 
[22/214], p=3.1e-03) (Table 3). 
 
In terms of individual mutations, BRAF c.1781A>G (p.D594G) CRCs had similar 
clinicopathology to wild type CRCs (Table 3). In contrast, more BRAF c.1799T>A 
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(p.V600E) CRCs were found in the right colon (47% [47/100] versus 12% [80/693], 
p<2.2e-16), and less in the rectum (11% [11/100] versus 34% [234/693], p=7.1e-06) 
and sigmoid colon (2% [2/100] versus 11% [73/693], p=3.2e-03) and more were 
associated with peritoneal metastases (24% [24/100] versus 12% [82/693], p=1.5e-
03) as compared to wild type CRCs; the correlations for right colon and rectum 
remained significant after correction for multiple testing (Table 3). 
 
In terms of intra-locus differences, there was a significant difference between 
c.1781A>G (p.D594G) and c.1799T>A (p.V600E) CRCs in the location of the 
primary tumour (p=9.3e-05, p=3.6e-03 after correction), due to fewer c.1781A>G 
(p.D594G) CRCs in the right colon (7% [1/15] versus 47% [47/100], p=3.7e-03), and 
more in the rectum (60% [9/15] versus 11% [11/100], p=1.7e-05, p=6.6e-04 after 
correction) (Table 3). There was no significant difference between the sites of 
metastases associated with these mutations. 
 
NRAS 
There was no difference between the frequency of NRAS mutant and wild type 
CRCs in the site of the primary tumour (Table 4). However, more NRAS mutant 
CRCs were associated with metastases in the lung (11% [43/400]) as compared to 
liver only (4% [10/272], p=1.4e-03). 
 
In terms of individual codons, codon 12 and 13 mutant CRCs showed similar 
clinicopathology to wild type CRCs (Table 4). Codon 61 mutant CRCs had similar 
primary tumour distributions but significantly fewer liver only (12% [7/57] versus 26% 
[262/1002], p=0.03) and more lung metastases (68% [39/57] versus 36% [357/1002], 
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p=1.3e-06, p=5.1e-05 after correction) as compared to wild type CRCs (Table 4). 
There were no significant differences in clinicopathology between codons 12 and 13 
versus codon 61 mutant CRCs. 
 
MSI 
More MSI CRCs were found in the right colon (41% [12/29] versus 12% [80/693], 
p=9.2e-06, p=1.2e-04 after correction) and less in the rectosigmoid junction (3% [1/29] 
versus 18% [126/693], p=0.04) and less were associated with liver metastases (48% 
[14/29] versus 77% [536/693], p=7.3e-04, p=9.5e-03 after correction) as compared to 
MSS CRCs (Table 5). 
 
DISCUSSION 
Variants in BRAF and NRAS have been presumed to confer similar oncogenic and 
prognostic outcomes; however, here we demonstrate clear intra-locus differences. 
For BRAF, c.1799T>A (p.V600E) was almost mutually exclusive of RAS mutations 
and was associated with poor prognosis. In contrast, c.1781A>G (p.D594G) was 
more often associated with RAS mutations and had no apparent influence on 
survival. However, c.1781A>G (p.D594G) is unlikely to be benign and more likely to 
be hypomorphic, as it had significantly fewer co-occurrences with RAS mutations as 
compared to BRAF wild type CRCs. Interestingly, our data are consistent with a 
recent report showing that patients with codon 594 or 596 mutated tumours had 
longer OS compared to those with c.1799T>A (p.V600E) CRCs (15). There are clear 
biological differences between these mutant codons to support our observed 
pathological differences; p.V600E increased extracellular signal-regulated kinase 
(ERK) and nuclear factor kappaB (NFκB) signalling and the transformation of 
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NIH3T3 cells, whereas p.D594V failed to activate ERK (16) and did not affect NFκB 
signalling nor NIH3T3 transforming activity (17). 
 
Others have reported that NRAS mutant patients have shorter OS as compared to 
wild type patients (HR 1.91, 95% CI 1.39-3.86; p=1.0e-03) (18). Here, we noted a 
more complex relationship; NRAS codon 61 mutations, which were rarely associated 
with KRAS mutations, conferred a poor prognosis, but codons 12 and 13 mutations, 
which co-occurred with KRAS mutations at similar frequencies to wild type CRCs, 
had little influence on survival. Together, our data suggest that NRAS codons 12 and 
13 mutations may have a minor role in colorectal tumourigenesis. Interestingly, using 
mouse models others have shown that endogenous levels of Nras p.Q61R, but not 
Nras p.G12D, were able to efficiently drive in vivo melanomagenesis (19), supporting 
their differing biological effects. 
 
We have also shown that different mutant loci are associated with differences in the 
clinicopathology of the primary tumours and/or their sites of metastases. For 
example, in agreement with two recent reports (20, 21), we observed more KRAS 
mutant CRCs in the caecum (70%) and, to a lesser extent, in the right colon (58%), 
as compared to the left colon (38%). It has been suggested that different somatic 
profiles are associated with different clinicopathology, by influencing the tumour's 
biological behaviour (22). Here, we focussed on intra-locus differences and found a 
significant difference between c.1781A>G (p.D594G) and c.1799T>A (p.V600E) in 
BRAF in the location of the primary tumour providing additional support for these 
variants having different biological effects. 
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In conclusion, our study shows considerable intra-locus variations in survival, 
particularly in the outcomes of mutations in BRAF and NRAS. These data need to be 
considered in patient management. 
 
ACKNOWLEDGEMENTS 
We thank the patients and their families who participated and gave their consent for 
this research, and the investigators and pathologists throughout the UK who 
submitted samples for assessment. COIN and COIN-B were coordinated by the 
Medical Research Council Clinical Trials Unit and conducted with the support of the 
National Institute of Health Research Cancer Research Network. 
17 
 
REFERENCES 
1. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic 
prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-
99. 
2. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et 
al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for 
metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann 
Oncol 2002;13:308-17. 
3. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and 
body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-7. 
4. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and 
mortality in relation to body mass index in the Million Women Study: cohort study. 
BMJ 2007;335:1134. 
5. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. 
Comparison of the prognostic value of selected markers of the systematic 
inflammatory response in patients with colorectal cancer. Br J Cancer 2007;97:1266-
70. 
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et 
al. Type, density and location of immune cells with human colorectal tumors predict 
clinical outcome. Science 2006;313:1960-4. 
7. Smith CG, Fisher D, Harris R, Maughan TS, Phipps AI, Richman SD, et al. 
Analyses of 7,635 patients with colorectal cancer using independent training and 
validation cohorts show that rs9929218 in CDH1 is a prognostic marker of survival. 
Clin Can Res 2015;21:3453-61. 
18 
 
8. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability 
and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18. 
9. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability 
and prognosis in colorectal cancer: a meta-analysis. Gut 2008;57:941-50. 
10. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. 
Microsatellite instability and BRAF mutation testing in colorectal cancer 
prognostication. J Natl Can Inst 2013;105:1151-6. 
11. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Johnsson BA, Oberg A, et al. The 
prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J 
Cancer 2013;108:2153-63. 
12. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. 
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for 
treatment of advanced colorectal cancer: results of the randomised phase 3 MRC 
COIN trial. The Lancet 2011;377:2103-14. 
13. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al. 
Somatic profiling of the epidermal growth factor receptor pathway in tumours from 
patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. 
Clin Can Res 2013;19:4104-13. 
14. Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent 
chemotherapy plus either intermittent or continuous cetuximab for first-line treatment 
of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised 
phase 2 trial. Lancet Oncol 2014;15:631-9. 
19 
 
15. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, et 
al. BRAF codons 594 and 596 mutations identify a new molecular subtype of 
metastatic colorectal cancer at favorable prognosis. Ann Oncol 2015;26:2092-7. 
16. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. 
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations 
of B-RAF. Cell 2004;116:855-67. 
17. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, et al. Functional 
analysis of mutations within the kinase activation segment of B-Raf in human 
colorectal tumors. Can Res 2003;63:8132-7. 
18. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. 
Role of NRAS mutations as prognostic and predictive markers in metastatic 
colorectal cancer. Int J Cancer 2015;136:83-90. 
19. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-
specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Can 
Discov 2014;4:1418-29. 
20. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. 
Assessment of colorectal cancer molecular features along bowel subsites challenges 
the conception of distinct dichotomy of proximal versus distal colorectum. Gut 
2012;61:847-54. 
21. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, et al. 
Colorectal carcinomas with KRAS mutation are associated with distinctive 
morphological and molecular features. Mod Pathol 2013;26:825-34. 
20 
 
22. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF 
mutation and microsatellite instability on the pattern of metastatic spread and 
prognosis in metastatic colorectal cancer. Cancer 2011;117:4623–32. 
21 
 
Table 1. Prognostic outcomes of individual mutations, or mutations grouped by codon or gene 
on OS. 
Gene/event Mutation/codon No of events1 HR 95% CIs p-value 
KRAS c.34G>A (p.G12S) 35 1.78 1.27-2.50 9.2e-04 (0.03) 
 c.34G>C (p.G12R) 10 0.95 0.51-1.78 0.88 
 c.34G>T (p.G12C) 52 1.21 0.91-1.60 0.18 
 c.35G>A (p.G12D) 187 1.48 1.26-1.74 1.6e-06 (4.8e-05) 
 c.35G>C (p.G12A) 41 1.43 1.04-1.96 0.03 
 c.35G>T (p.G12V) 161 1.48 1.25-1.76 7.5e-06 (2.3e-04) 
 c.37G>T (p.G13C) 6 1.36 0.61-3.03 0.46 
 c.38G>A (p.G13D) 116 1.53 1.26-1.87 2.2e-05 (6.6e-04) 
 c.38G>T (p.G13V) 1 - - - 
 c.182A>G (p.Q61R) 6 1.41 0.63-3.15 0.41 
 c.182A>T (p.Q61L) 6 1.27 0.57-2.84 0.56 
 c.183A>C (p.Q61H) 15 1.17 0.70-1.95 0.56 
 Codon 12 486 1.44 1.28-1.61 6.4e-10 (1.9e-08) 
 Codon 13 123 1.53 1.26-1.86 1.5e-05 (4.5e-04) 
 Codon 61 27 1.23 0.84-1.81 0.28 
 Any KRAS mutation 632 1.45 1.30-1.61 1.9e-11 (5.7e-10) 
      
BRAF c.1781A>G (p.D594G) 12 1.30 0.73-2.31 0.37 
 c.1799T>A (p.V600E) 87 2.60 2.06-3.28 1.0e-15 (3.0e-14) 
 Any BRAF mutation 99 2.31 1.85-2.87 7.8e-14 (2.3e-12) 
      
NRAS c.34G>T (p.G12C) 5 1.42 0.59-3.43 0.43 
 c.35G>A (p.G12D) 2 - - - 
 c.35G>T (p.G12V) 1  - - - 
 c.181C>A (p.Q61K) 21 1.43 0.96-2.21 0.11 
 c.182A>G (p.Q61R) 13 1.58 0.91-2.73 0.11 
 c.182A>T (p.Q61L) 11 1.51 0.83-2.73 0.18 
 Codons 12 and 13 8 1.29 0.64-2.58 0.48 
 Codon 61 45 1.47 1.09-1.99 0.01 
 Any NRAS mutation 53 1.44 1.09-1.90 0.01 
      
MSI MSI 23 1.86 1.22-2.83 4.0e-03 
 MSS 476 1.00 ref. ref. 
 
KRAS mutants (versus wild type) were analysed on a BRAF and NRAS wild type background; BRAF mutants 
(versus wild type) were analysed on a RAS wild type and MSS background; NRAS mutants (versus wild type) 
were analysed on a KRAS and BRAF wild type background; and MSI (versus MSS) was analysed on a RAS and 
BRAF wild type background. Number of events, HR, CIs and p-values are shown (except for cases where 
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number of events ≤2). 1Mutations not listed when number of events=0. p-values that remained significant after 
correction for multiple testing are shown in parentheses. 
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Table 2: Clinicopathology according to KRAS mutation status 
 
Characteristics  Frequency of 
KRAS 
mutations1 
codons 12 and 
13 (n= 760) 
codon 61 (n= 
33) 
wild type (n= 
1002) 
p (codons 12 and 
13 vs. wild type) 
p (codon 61 
vs. wild type) 
p (codons 12 and 
13 vs. codon 61) 
Sex Female 289/593 (49) 275 (36) 14 (42) 304 (30) 0.01 0.20 0.59 
Male 503/1201 (42) 485 (64) 19 (58) 698 (70) 0.01 0.20 0.59 
         
Age Mean NA 63 61  63 NA NA NA 
         
Primary 
Tumour Site 
Right Colon 182/314 (58) 173 (23) 9 (27) 132 (13) 1.9e-07 [7.4e-06] 0.04 0.70 
Caecum 62/88 (70) 61 (8) 1 (3) 26 (3) 3.4e-07 [1.3e-05] 0.59 0.51 
Transverse 
Colon 
14/35 (40) 14 (2) 0 (0) 21 (2) 0.84 1.0 1.0 
Left Colon 123/326 (38) 117 (15) 6 (18) 203 (20) 0.01 0.94 0.85 
Sigmoid Colon 44/159 (28) 41 (5) 3 (9) 115 (11) 1.3e-05 [5.1e-04] 1.0 0.42 
Rectosigmoid 
Junction 
108/269 (40) 105 (14) 3 (9) 161 (16) 0.22 0.34 0.61 
Rectum 251/577 (44) 241 (32) 10 (30) 326 (33) 0.75 0.94 1.0 
         
Site of 
Metastases2 
Liver Only 156/418 (37) 152 (20) 4 (12) 262 (26) 3.1e-03 0.07 0.37 
Liver 598/1356 (44) 577 (76) 22 (67) 758 (76) 0.94 0.33 0.32 
Nodal 359/832 (43) 345 (45) 15 (45) 473 (47) 0.48 0.98 1.0 
Lung 358/715 (50) 342 (45) 16 (48) 357 (36) 8.4e-05 [3.3e-03] 0.18 0.83 
Peritoneum 126/259 (49) 117 (15) 9 (27) 133 (13) 0.23 0.04 0.11 
 
Mutations were analysed on an NRAS and BRAF wild type background. 1There was a significant difference between KRAS mutant CRCs in the location of the primary tumour 
(p=6.4e-14) and in the sites of metastases (p=4.6e-04) as compared to wild type CRCs. Percentages are shown in regular parentheses (2some patients had multiple metastases 
so percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA - not applicable. 
Discrepancies in column totals are due to patients with multiple mutations or due to missing data.  
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 Table 3: Clinicopathology according to BRAF mutation status 
 
Characteristics  Frequency of 
BRAF 
mutations1 
c.1781A>G 
(p.D594G) 
(n = 15) 
c.1799T>A 
(p.V600E) 
(n = 100) 
wild type 
(n = 693) 
p (c.1781A>G 
[p.D594G] vs. 
wild type) 
p (c.1799T>A 
[p.V600E] vs. wild 
type) 
p (c.1781A>G 
[p.D594G] vs. 
c.1799T>A [p.V600E)) 
Sex Female 55/249 (22) 7 (47) 48 (48) 194 (28) 0.20 8.0e-05 [3.1e-03] 1.0 
Male 60/559 (11) 8 (53) 52 (52) 499 (72) 0.20 8.0e-05 [3.1e-03] 1.0 
         
Age Mean NA 67 63 63 NA NA NA 
         
Primary 
Tumour Site 
Right Colon 48/128 (38) 1 (7) 47 (47) 80 (12) 1.0 <2.2e-16 [<8.6e-15] 3.7e-03 
Caecum 4/24 (17) 0 (0) 4 (4) 20 (3) 1.0 0.53 1.0 
Transverse Colon 4/20 (20) 0 (0) 4 (4) 16 (2) 1.0 0.30 1.0 
Left Colon 18/146 (12) 1 (7) 17 (17) 128 (18) 0.34 0.83 0.46 
Sigmoid Colon 4/77 (5) 2 (13) 2 (2) 73 (11) 0.67 3.2e-03 0.08 
Rectosigmoid 
Junction 
15/141 (11) 2 (13) 13 (13) 126 (18) 1.0 0.26 1.0 
Rectum 20/254 (8) 9 (60) 11 (11) 234 (34) 0.07 7.1e-06 [2.8e-04] 1.7e-05 [6.6e-04] 
         
Site of 
Metastases2 
Liver Only 22/214 (10) 3 (20) 19 (19) 192 (28) 0.77 0.09 1.0 
Liver 83/619 (13) 13 (87) 70 (70) 536 (77) 0.54 0.14 0.23 
Nodal 53/368 (14) 7 (47) 46 (46) 315 (45) 1.0 1.0 1.0 
Lung 35/272 (13) 6 (40) 29 (29) 237 (34) 0.85 0.36 0.57 
Peritoneum 25/107 (23) 1 (7) 24 (24) 82 (12) 1.0 1.5e-03 0.19 
 
Mutations analysed on a RAS wild type and MSS background. 1There was a significant difference between BRAF mutant CRCs in the location of the primary tumour (p=1.2e-13) and in the sites of metastases (p=0.03) as compared to wild type CRCs. Percentages are shown in regular parentheses (2some patients had multiple metastases so 
percentages do not add up to 100%). p-values that remained significant after correction for multiple testing are shown in square parentheses. NA - not applicable. 
Discrepancies in column totals are due to patients with multiple mutations or due to missing data. 
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Table 4: Clinicopathology according to NRAS mutation status 
 
Characteristics  Frequency of 
NRAS 
mutations1 
codons 12 and 
13 (n = 11) 
codon 61 (n = 
57) 
wild type (n = 
1002) 
p (codons 12 
and 13 vs. wild 
type) 
p (codon 61 vs. 
wild type) 
p (codons 12 
and 13 vs. 
codon 61) 
Sex Female 20/324 (6) 2 (18) 18 (32) 304 (30) 0.52 0.96 0.49 
Male 48/746 (6) 9 (82) 39 (68) 698 (70) 0.52 0.96 0.49 
         
Age Mean NA 59 62 63 NA NA NA 
         
Primary 
Tumour Site 
Right Colon 5/137 (4) 2 (18) 3 (5) 132 (13) 0.65 0.10 0.18 
Caecum 4/30 (13) 0 (0) 4 (7) 26 (3) 1.0 0.07 1.0 
Transverse Colon 3/24 (13) 0 (0) 3 (5) 21 (2) 1.0 0.13 1.0 
Left Colon 12/215 (6) 1 (9) 11 (19) 203 (20) 0.70 1.0 0.67 
Sigmoid Colon 11/126 (9) 2 (18) 9 (16) 115 (11) 0.37 0.44 1.0 
Rectosigmoid 
Junction 
10/171 (6) 0 (0) 10 (18) 161 (16) 0.23 0.91 0.20 
Rectum 19/345 (6) 6 (55) 13 (23) 326 (33) 0.22 0.17 0.08 
         
Site of 
Metastases2 
Liver Only 10/272 (4) 3 (27) 7 (12) 262 (26) 1.0 0.03 0.35 
Liver 52/810 (6) 8 (73) 44 (77) 758 (76) 0.74 0.92 0.71 
Nodal 35/508 (7) 3 (27) 32 (56) 473 (47) 0.23 0.24 0.11 
Lung 43/400 (11) 4 (36) 39 (68) 357 (36) 1.0 1.3e-06 [5.1e-05] 0.08 
Peritoneum 5/138 (4) 1 (9) 4 (7) 133 (13) 1.0 0.22 1.0 
 
Mutations analysed on a KRAS and BRAF wild type background. 1There was a significant difference between NRAS mutant CRCs in the sites of metastases (p=2.5e-03) as 
compared to wild type CRCs. Percentages are shown in regular parentheses (2some patients had multiple metastases so percentages do not add up to 100%). p-values that 
remained significant after correction for multiple testing are shown in square parentheses. NA - not applicable. Discrepancies in column totals are due to patients with multiple 
mutations or due to missing data. 
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Table 5: Clinicopathology according to MSI status 
 
Characteristics  Frequency of MSI1  MSI (n=29) MSS (n=693) p (MSI vs. MSS) 
Sex Female 11/205 (5) 11 (38) 194 (28) 0.34 
Male 18/517 (3) 18 (62) 499 (72) 0.34 
      
Age Mean NA 58  63 NA 
      
Primary Tumour 
Site 
Right Colon 12/92 (13) 12 (41) 80 (12) 9.2e-06 [1.2e-04] 
Caecum 1/21 (5) 1 (3)  20 (3) 0.58 
Transverse Colon 1/17 (6) 1 (3) 16 (2) 0.51 
Left Colon 7/135 (5) 7 (24) 128 (18) 0.60 
Sigmoid Colon 1/76 (1) 1 (3) 73 (11) 0.35 
Rectosigmoid 
Junction 
1/127 (1) 1 (3) 126 (18) 0.04 
Rectum 6/240 (3) 6 (21) 234 (34) 0.21 
      
Site of 
Metastases2 
Liver Only 3/195 (2) 3 (10) 192 (28) 0.05 
Liver 14/550 (3) 14 (48) 536 (77) 7.3e-04 [9.5e-03] 
Nodal 17/332 (5) 17 (59) 315 (45) 0.23 
Lung 6/243 (2)  6 (21) 237 (34) 0.19 
Peritoneum 7/89 (8)  7 (24) 82 (12) 0.09 
 
MSI status was analysed on an RAS and BRAF wild type background. 1There was a significant difference between MSI CRCs in the 
location of the primary tumour (p=2.5e-04) and in the sites of metastases (p=0.02) as compared to MSS CRCs. Percentages are shown in 
regular parentheses (2some patients had multiple metastases so percentages do not add up to 100%). p-values that remained significant 
after correction for multiple testing are shown in square parentheses. NA - not applicable. Discrepancies in column totals are due to 
patients with multiple mutations or due to missing data. 
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LEGEND TO FIGURE 
Figure 1. Kaplan-Meier plots showing the prognostic outcome of (A) c.1781A>G 
(p.D594G) and c.1799T>A (p.V600E) in BRAF, and (B) codons 12 and 13 and 
codon 61 mutations in NRAS. 
 

